“Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.

The findings add to a growing body of evidence that the GLP-1 drugs, which also include Novo Nordisk’s Ozempic and Wegovy, have benefits beyond diabetes and weight loss. 

In Lilly’s latest trial, patients who got tirzepatide were 38% less likely to be hospitalized, need to increase their heart failure medication or die because of heart complications, compared to people who got a placebo. Patients who got the drug also reported less shortness of breath, fatigue and swelling of the lower legs. The trial lasted 52 weeks.”

From NBC News.